New immunotherapy cocktail aims to simplify cancer treatment

NCT ID NCT05661578

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the safety and how the drugs move through the body, not to measure how well they fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tiragolumab and atezolizumab (immunotherapy drugs given together as a fixed-dose combination)
What this could lead to: If successful, this could provide a more convenient way to deliver a promising immunotherapy combination for certain advanced solid tumors.
What could go wrong: This is a small, early-phase study focused on safety and drug levels, not on how well the treatment works. The combination may not prove effective or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PD-L1-SELECTED SOLID TUMORS

Contacts and locations

Locations

Asan Medical Center - PPDS

Seoul, 05505, South Korea
C.H. Regional Reina Sofia - PPDS

Córdoba, 14004, Spain
China Medical University Hospital

Taichung, 40447, Taiwan
Chongqing Sanxia Central Hospital

Chongqing, 404000, China
Gazi University Medical Faculty

Ankara, 06500, Turkey (Türkiye)
General Hospital Pula

Pula, 52000, Croatia
Hacettepe Universitesi Tip Fakultesi Hastanesi

Ankara, 06100, Turkey (Türkiye)
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Regional Universitario de Malaga ? Hospital General

Málaga, 29010, Spain
Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Hospital del Mar

Barcelona, 08003, Spain
IASO Obstetrics Gynecology Clinic

Marousi, 151 23, Greece
ICO l?Hospitalet ? Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Inonu University Faculty of Medicine Turgut Ozal Medical Center

Malatya, 44280, Turkey (Türkiye)
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

Barcelona, 8035, Spain
Klinicki bolnicki centar Zagreb

Zagreb, 10000, Croatia
Medical Oncology Associates

Spokane, Washington, 99208, United States
Medical Park Seyhan Hospital

Seyhan, 01060, Turkey (Türkiye)
Memorial Ankara Hastanesi

Ankara, 06520, Turkey (Türkiye)
Memorial Sisli Private Hospital

Istanbul, 34385, Turkey (Türkiye)
Namik Kemal University

Alt?nova, 59100, Turkey (Türkiye)
National Cancer Center

Goyang-si, 10408, South Korea
National Cheng Kung University Hospital

Tainan, 70457, Taiwan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Oncology Institute of Vojvodina

Kamenitz, 21204, Serbia
START MADRID_Hospital Universiario Fundacion Jimenez Diaz

Madrid, 28040, Spain
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC

Madrid, 28050, Spain
Seoul National University Bundang Hospital

Seongnam-si, 13605, South Korea
St. Luke's Hospital

Thessaloniki, 552 36, Greece
TAIPEI VETERANS GENERAL HOSPITAL, Urology

Taipei, 11217, Taiwan
University General Hospital of Patras

Pátrai, 265 00, Greece
University Hospital Medical Center Bezanijska kosa

Belgrade, 11080, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.